Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer

Chen, Enli; Wang, Juan; Zhang, Hongtao; Zhang, Yuwei; Jia, Chenfei; Min, Xueya; Liang, Yaru

doi:10.5114/jcb.2021.106241

Cited by 8 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Implanted iodine-125 seeds can continuously release low-dose γ-rays and X-rays, with a radiation radius of 1.7 cm and a half-life of 59.6 days. Iodine-125 seeds release a cumulative radiation dose of 110-160 Gy in 8-10 months, with only a negligible radiation dose to surrounding tissues [ 11 ]; therefore, brachytherapy is a highly precise local therapy, and is superior to SBRT in terms of extremely low-risk of radiation-related adverse reaction [ 23 ]. This advantage is more obvious in peripherally and centrally located tumors, just as in our cases.…”

Section: Discussionmentioning

confidence: 99%

Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy: A report of two cases and literature review

Yuan¹,

Wang²,

Yang³

et al. 2023

jcb

View full text Add to dashboard Cite

Although immunotherapy regimens for advanced non-small-cell lung cancer (NSCLC) improve survival in selected sub-populations, their efficacy remains far from ideal due to underlying resistance; therefore, multimodal combination strategies are needed to optimize their efficacy. In our report, two patients with advanced NSCLC with negative targetable mutations, who had failed first-line chemotherapy were treated with combined therapy of computed tomography (CT)-guided percutaneous iodine-125 seed implantation and pembrolizumab. After combination treatment, both patients achieved partial response (PR), and sustained a long progression-free survival (PFS) without obvious therapy-related adverse reactions. Iodine-125 seeds bring no long-term adverse events and effectively amplify anti-tumor immune response induced by immunotherapy; thus, this combined therapy might be a promising alternative for NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy: A report of two cases and literature review

Yuan¹,

Wang²,

Yang³

et al. 2023

jcb

View full text Add to dashboard Cite

show abstract

“…5 Computational and Mathematical Methods in Medicine of CT imaging big data-assisted arterial chemoembolization combined with 125 I seed implantation for NSCLC was higher than arterial chemoembolization alone, without significantly increasing the incidence of adverse reactions, suggesting that the combination treatment can effectively inhibit NSCLC progression. The reason for the results may be that 125 I radioactive seeds are a kind of long half-life particles and can emit continuously low energy gamma rays, which can enhance the self-sensitization of the tumor cells and improve the sensitivity and killability of cancer cells, thus greatly improving treatment effect [19,20].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Evaluation of CT Imaging Big Data-Assisted Arterial Chemoembolization Combined with 125I Seed Implantation for Non-Small-Cell Lung Cancer

Xie

Zhang

2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. To investigate the prognostic impact of computed tomography (CT) imaging big data-assisted arterial chemoembolization combined with iodine 125 (125I) seed implantation on patients with non-small-cell lung cancer (NSCLC). Methods. A total of 116 patients with intermediate and advanced NSCLC hospitalized in our hospital from August 2019 to August 2020 were selected and divided into a control group and an experiment group (58 cases in each group) by random number table method for the study. The patients in the experiment group were treated with CT imaging big data-assisted arterial chemoembolization combined with 125I seed implantation, while the patients in the control group were treated with arterial chemoembolization alone, with the use of gemcitabine combined with cisplatin (GP) in chemotherapy. The prognostic impact was determined by analyzing recent efficacy; the incidence of adverse effects; tumor size and CT perfusion parameters including blood volume (BV), blood flow (BF), and permeability surface (PS); frailty state and quality of life; and the levels of serum tumor markers including carcinoembryonic antigen (CEA), glycoconjugate antigen 125 (CA125), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), microRNA- (miRNA-) 137, and miR-379-5p. In addition, frailty status was evaluated using the Fried frailty phenotype (FP) scale, and quality of life was determined according to Karnofsky Performance Status (KPS) score. Kaplan-Meyer (KM) method was used to analyze the survival rate of NSCLC patients after a 12-month follow-up. Results. The remission rate in the experiment group (77.59%) was higher than that in the control group (56.90%) ( P < 0.05 ). Tumor size, BV, BF, PS, serum CEA and CA125 levels, and FP value in both groups were dramatically reduced after treatment compared with before treatment, especially in the experiment group after 1 and 3 months of treatment ( P < 0.05 ). Meanwhile, the serum miR-137 and miR-379-5p levels and KPS scores in both groups were higher after treatment than before treatment, especially in the experiment group after 1 and 3 months of treatment ( P < 0.05 ). However, there was no significant difference in the incidence of nausea and vomiting, alopecia, diarrhea, myelosuppression, and hemoptysis of NSCLC patients in both groups after treatment ( P > 0.05 ). Further, the 12-month survival rate of NSCLC patients was higher in the experiment group (84.21%) than in the control group (64.29%) ( P < 0.05 ). Conclusion. CT imaging big data-assisted arterial chemoembolization combined with 125I seed implantation for NSCLC can improve recent efficacy and the prognosis of NSCLC patients by inhibiting tumor progression with a certain degree of safety.

show abstract

“…Chen E. et al and Li et al studied brachytherapy without concomitant therapies and reported an efficiency of 90% and a local control (LC) rate of 99% when treating NSCLC. [ 26 , 27 ]. An increase in LC was related to a prescription dose higher than 120 Gy.…”

Section: Endobronchial Administrationmentioning

confidence: 99%

“…The addition of brachytherapy to the other modalities showed an increased effect, OS, PFS and QOL. The most common AEs related to internal radiotherapy are pneumothorax (19%), bleeding (14%) and radiation pneumonitis (6%) [ 26 , 27 ].…”

Section: Endobronchial Administrationmentioning

confidence: 99%

“…[ 30 ] RCT NSCLC Advanced BT ChT 57 45 ChT n/a Wang, X. [ 31 ] RCT NSCLC IIIB, IV BT EGFR-TKI 54 54 EGFR-TKI n/a Chen, E. [ 26 ] Meta-analysis NSCLC Early-stage BT 308 n/a Chen, S. [ 28 ] RCT NSCLC I, IIA, III BT RFA 15 15 RFA n/a Chen, Z.K. [ 29 ] Meta-analysis NSCLC III, IV BT ChT 259 257 ChT n/a Endobronchial radiofrequency ablation Author Study Type Stages Groups N ...…”

Section: Table A1mentioning

confidence: 99%

See 1 more Smart Citation

Innovative Invasive Loco-Regional Techniques for the Treatment of Lung Cancer

Claes

Wener

Neyrinck

et al. 2023

Cancers

View full text Add to dashboard Cite

Surgical resection is still the standard treatment for early-stage lung cancer. A multimodal treatment consisting of chemotherapy, radiotherapy and/or immunotherapy is advised for more advanced disease stages (stages IIb, III and IV). The role of surgery in these stages is limited to very specific indications. Regional treatment techniques are being introduced at a high speed because of improved technology and their possible advantages over traditional surgery. This review includes an overview of established and promising innovative invasive loco-regional techniques stratified based on the route of administration, including endobronchial, endovascular and transthoracic routes, a discussion of the results for each method, and an overview of their implementation and effectiveness.

show abstract

Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer

Cited by 8 publications

References 35 publications

Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy: A report of two cases and literature review

Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy: A report of two cases and literature review

Prognostic Evaluation of CT Imaging Big Data-Assisted Arterial Chemoembolization Combined with 125I Seed Implantation for Non-Small-Cell Lung Cancer

Innovative Invasive Loco-Regional Techniques for the Treatment of Lung Cancer

Contact Info

Product

Resources

About